The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Neomile Growth Fund - Series I
AHCL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.8 pts more than Nifty Microcap 250 and 3.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Neomile Growth Fund - Series I, along with PAC Neomile Corporate Advisory Limited, sold 14,75,992 equity shares (2.78%) of Anlon Healthcare Ltd in the open market between November 3 and November 4, 2025. The seller is not part of the promoter/promoter group. Before the sale, the fund held 55,28,667 shares (10.40% of total equity), which has now come down to 40,52,675 shares (7.62%). The disclosure was filed under SEBI's Substantial Acquisition of Shares & Takeovers Regulations, 2011, triggered because the fund crossed below the 10% substantial shareholder threshold. Anlon Healthcare's total equity share capital remains unchanged at 5,31,51,500 shares.
A non-promoter institutional investor has trimmed its stake meaningfully and dropped below the 10% significant-shareholder mark. For retail investors, this signals a large fund reducing conviction in the stock, which may weigh on short-term sentiment, though no promoter-level changes are involved.